Amid reports of severe brain inflammation and deaths linked to side effects of Zinbryta, the multiple sclerosis drug was recalled globally in early March 2018. As a result of the drug makers failure to warn about the risk of encephalitis, meningoencephalitis and other problems, Zinbryta lawsuits are being evaluated by product liability lawyers. STATUS OF ZINBRYTA LAWSUITS: Lawyers are evaluating whether financial compensation may be available for individuals who have experienced any of the following complications following use of Zinbryta: Encephalitis Meningoencephalitis Other Sudden Brain Inflammation Wrongful Death >>SUBMIT INFO TO A ZINBRYTA LAWYER<< MANUFACTURERS: AbbVie, Inc. and Biogen, Inc.…
European regulators say they have positively confirmed that the recently recalled MS drug Zinbryta had health risks that outweighed any potential benefits, indicating that causes of severe brain inflammation were impossible to predict.…
A new study indicates that Zinbryta side effects were so severe it could have never become a major drug product, raising questions as to why it was approved when there were less dangerous alternatives.…
The FDA says it will help multiple sclerosis patients transition to other drugs following a Zinbryta recall, and will let it stay on the market until the end of April.…
A Zinbryta recall has been announced following 12 cases of brain inflammation, including three deaths, linked to use of the multiple sclerosis drug.…
A Zinbryta recall and ban has been recommended in the EU following a dozen reports of serious brain inflammation linked to at least three patient deaths.…
